Payment overview · 2025
General Payments
$1,882.21
87 reported records · 22 companies
Healthcare provider profile · identity verified
Carl J Kinzel, DO
Allopathic & Osteopathic Physicians|Family Medicine · BATTLE CREEK, MI · NPI 1992983209
Verified facts
What the public records show
CMS Open Payments records show Carl J Kinzel, DO received $1,882.21 in general payments during 2025 across 87 reported records.
Novo Nordisk Inc accounted for 11.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.84 | 11.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.56 | 10.8% | 8 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $182.01 | 9.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $165.84 | 8.8% | 9 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $165.34 | 8.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $155.30 | 8.2% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $111.33 | 5.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $101.90 | 5.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.56 | 3.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.65 | 3.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.62 | 3.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.97 | 2.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.95 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.25 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.13 | 2.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.90 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.62 | 2.0% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.39 | 1.9% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $33.54 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.91 | 1.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.24 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.36 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,882.21 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $182.01 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $165.84 | 9 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $165.34 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $160.33 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $160.02 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $155.30 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $151.46 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $133.45 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.90 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $88.02 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.97 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.03 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.90 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $33.54 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 31 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
161 | 38 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 674 | 102 |
| Alprazolam | Alprazolam | 262 | 53 |
| Lisinopril | Lisinopril | 234 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 65 |
| Omeprazole | Omeprazole | 201 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 66 |
| Gabapentin | Gabapentin | 178 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 176 | 57 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 161 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 26 |
| Metformin Hcl | Metformin Hcl | 132 | 39 |
| Montelukast Sodium | Montelukast Sodium | 132 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 37 |
| Losartan Potassium | Losartan Potassium | 113 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 40 |
| Morphine Sulfate Er | Morphine Sulfate | 111 | 12 |
| Potassium Chloride | Potassium Chloride | 103 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 33 |
| Ozempic | Semaglutide | 100 | 23 |
| Furosemide | Furosemide | 94 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 33 |
| Trazodone Hcl | Trazodone Hcl | 84 | 28 |
| Simvastatin | Simvastatin | 75 | 22 |
| Fentanyl | Fentanyl | 74 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 21 |
| Celecoxib | Celecoxib | 62 | 15 |
| Tramadol Hcl | Tramadol Hcl | 62 | 16 |
| Chlorthalidone | Chlorthalidone | 61 | 21 |
| Farxiga | Dapagliflozin Propanediol | 60 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 15 |
| Buspirone Hcl | Buspirone Hcl | 57 | 18 |
| Pregabalin | Pregabalin | 57 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 15 |
| Lorazepam | Lorazepam | 52 | 11 |
| Sertraline Hcl | Sertraline Hcl | 50 | 11 |
| Ibuprofen | Ibuprofen | 48 | 12 |
| Meloxicam | Meloxicam | 48 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Eliquis | Apixaban | 31 | 15 |
| Morphine Sulfate | Morphine Sulfate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 11 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 12 |
| Linzess | Linaclotide | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | 11 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,882.21 · 87 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, Belbuca, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, INJECTAFER, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, REPATHA, REXULTI, RINVOQ, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error